Research__O reference__O 2__O above__O led__O to__O immediate__O interest__O by__O the__O pharmaceutical__O industry.__O
A__O large__O body__O of__O in__O vitro__O and__O in__O vivo__O evidence__O supports__O the__O hypothesis__O that__O disrupting__O the__O Nrf2/Keap1__B-ORG interaction__O is__O a__O valid__O approach__O for__O anti-inflammatory__O therapy.__O
Traditionally,__O the__O disruption__O of__O such__O protein-protein__O interactions__O has__O been__O highly__O challenging__O for__O the__O pharmaceutical__O industry.__O
Nevertheless,__O small__O molecules__O had__O been__O found__O that__O bind__O to__O Keap1__B-ORG and__O prevent__O its__O interaction__O with__O Nrf2.__B-ORG
Although__O one__O of__O these__O (bardoxolone)__O has__O entered__O clinical__O trials,__O it__O attaches__O to__O Keap1__B-ORG covalently,__O with__O the__O potential__O for__O undesired__O side__O effects__O by__O nonspecific__O binding.__O
It__O would__O be__O preferable__O to__O achieve__O Keap1__B-PER blockage__O with__O a__O reversible__O competitive__O ligand,__O and__O work__O by__O O'Connell__B-ORG and__O Searcey__B-ORG was__O the__O first__O to__O show__O that__O the__O Nrf2/Keap1__B-MISC interaction__O can__O be__O blocked__O in__O cells__O by__O a__O reversible__O ligand,__O provided__O that__O the__O molecule__O has__O high__O cell__O permeability.__O
The__O results__O provide__O a__O valuable__O proof__O of__O concept__O that__O reversible__O Nrf2/Keap1__B-ORG disruption__O has__O the__O same__O anti-inflammatory__O effects__O in__O cells__O as__O the__O earlier__O irreversible__O approach.__O
This__O discovery__O lays__O the__O foundation__O for__O the__O discovery__O of__O second__O generation__O reversible__O ligands__O with__O improved__O drug-like__O properties__O over__O the__O original__O peptides.__O
Searcey__O was__O contacted__O by__O Novartis,__B-PER who__O requested__O samples__O of__O the__O peptide__O TAT14__O for__O their__O research.__O
To__O quote__O [text__O removed__O for__O publication]__O at__O Novartis__O UK:__O [text__O removed__O for__O publication]__O (Corroborative__B-MISC source__O A)__O Later,__B-PER Novartis__I-PER had__O a__O contract__O company__O make__O the__O peptide__O as__O the__O amount__O needed__O was__O too__O large__O for__O the__O Searcey__B-MISC group__O to__O synthesise__O in-house.__O
Independently,__B-PER AstraZeneca__I-PER showed__O interest__O in__O the__O activity__O of__O TAT14__O and__O carried__O out__O studies__O in__O their__O own__O laboratories,__O including__O Surface__B-ORG Plasmon__I-ORG Resonance__I-ORG (SPR)__I-ORG and__O other__O techniques__O to__O quantify__O the__O binding__O between__O the__O peptide__O and__O Keap1.__B-LOC
Following__O these__O expressions__O of__O interest__O from__O the__O pharmaceutical__O industry,__O TAT14__B-MISC is__O already__O available__O in__O the__O catalogues__O of__O two__O pharmaceutical/fine__O chemical__O companies.__O
In__O 2013,__B-ORG Searcey__I-ORG was__O approached__O by__O the__O biotech__O company__O Tocris__B-ORG Bioscience__I-ORG to__O discuss__O the__O sale__O of__O the__O TAT14__B-MISC peptide__O as__O a__O chemical__O biology__O tool.__O
Tocris__O describes__O the__O utility__O of__O TAT14__O as__O follows:__O "Currently,__O there__O are__O very__O few__O pharmacologically__O active__O and__O commercially__O available__O tools__O for__O studying__O this__O (Nrf2)__B-MISC transcription__O factor__O in__O cell__O culture.__O
Nrf2__O activation__O tends__O to__O be__O an__O ancillary__O activity__O for__O most__O of__O the__O small__O molecules__O Tocris__B-MISC sells__O for__O this__O target__O (e.g.__O
curcumin,__O andrographolide,__O methyl__O fumarates).__O
Therefore,__O a__O peptide__O selectively__O targeting__O Nrf2,__B-MISC particularly__O one__O with__O proven__O cellular__O activity__O should__O prove__O to__O be__O an__O important__O tool__O in__O the__O arsenal__O for__O cell__O biologists__O studying__O cellular__O stress__O mediated__O through__O the__O Nrf2/Keap1__B-ORG pathway."__O
(Corroborative__B-LOC source__O B).__O
Tocris__B-PER made__O TAT14__O available__O for__O sale__O in__O March__O 2013__O and__O cite__O reference__O 2__O above__O on__O their__O web__O page__O (Corroborative__B-MISC source__O C).__B-ORG
Within__O a__O few__O months,__O they__O had__O sold__O [text__O removed__O for__O publication]__O TAT14.__O
[text__O removed__O for__O publication]__O the__O commercial__O potential__O of__O TAT14__B-ORG will__O only__O be__O known__O after__O a__O full__O year__O on__O the__O market.__O
Meanwhile,__O the__O American__B-MISC biotech__O company,__O EMD__O Millipore__O Chemicals__O (also__O known__O as__O Calbiochem),__B-ORG has__O introduced__O TAT14__O for__O sale__O (Corroborative__O source__O D).__O
Although__O this__O research__O was__O only__O published__O in__O 2012,__O the__O commercialisation__O by__O two__O companies__O less__O than__O a__O year__O later__O highlights__O the__O utility__O of__O TAT14__O for__O inflammation__O research__O and__O drug__O discovery.__O
